Aurinia Pharmaceuticals Inc. specializes in the research, development, and commercialization of treatments for targeted patient populations suffering from autoimmune diseases. The company's primary commercial asset is LUPKYNIS (voclosporin), a structurally modified calcineurin inhibitor used to treat active lupus nephritis (LN). Aurinia markets LUPKYNIS directly to specialty pharmacies and distributors in the United States, while partnering with Otsuka Pharmaceutical Co., Ltd. for commercialization in Europe and Japan. Beyond its marketed product, the company is advancing its clinical pipeline, which includes aritinercept (AUR200), a novel biologic and dual inhibitor of BAFF and APRIL being evaluated for autoimmune conditions. Originally founded as Isotechnika in 1993, the company assumed its current form following a 2013 merger.
